» Articles » PMID: 20199761

Marker Vaccine Potential of a Foot-and-mouth Disease Virus with a Partial VP1 G-H Loop Deletion

Overview
Journal Vaccine
Date 2010 Mar 5
PMID 20199761
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Previous work in cattle and pigs demonstrated that protection against foot-and-mouth disease (FMD) could be achieved following vaccination with chimeric foot-and-mouth disease virus (FMDV) vaccines, in which the VP1 G-H loop had been substituted with that from another serotype. This indicated that the VP1 G-H loop may not be essential for the protection of natural hosts against FMDV. If this could be substantiated there would be potential to develop FMD marker vaccines, characterised by the absence of this region. Here, we investigate the serological responses to vaccination with a virus with a partial VP1 G-H loop deletion in order to determine the likelihood of achieving protection and the potential of this virus as a marker vaccine. Inactivated, oil adjuvanted, vaccines, consisting of chemically inactivated virus with or without a partially deleted VP1 G-H loop, were used to immunise cattle. Serum was collected on days 0, 7, 14 and 21 and antibody titres calculated using the virus neutralisation test (VNT) to estimate the likelihood of protection. We predict a good likelihood that cattle vaccinated with a vaccine characterised by a partial VP1 G-H loop would be protected against challenge with the same virus containing the VP1 G-H loop. We also present evidence on the potential of such a construct to act as a marker vaccine, when used in conjunction with a novel serological test.

Citing Articles

Levamisole, as a viral vaccine adjuvant, induces robust host defense through the modulation of innate and adaptive immune responses.

Kim G, Kwak D, Kim H, Shin S, Ko M, Hwang S Front Microbiol. 2025; 15():1493561.

PMID: 39845058 PMC: 11751227. DOI: 10.3389/fmicb.2024.1493561.


Next-generation adjuvant systems containing furfurman drives potent adaptive immunity and host defense as a foot-and-mouth disease vaccine adjuvant.

Kim H, Shin S, Park S, Park J, Kim S, Lee Y Front Immunol. 2025; 15:1491043.

PMID: 39742276 PMC: 11687127. DOI: 10.3389/fimmu.2024.1491043.


Enhanced Effects of ISA 207 Adjuvant via Intradermal Route in Foot-and-Mouth Disease Vaccine for Pigs.

Hwang J, Lee K, Kim S, Kim H, Park S, Kim D Vaccines (Basel). 2024; 12(9).

PMID: 39339996 PMC: 11435775. DOI: 10.3390/vaccines12090963.


Isoprinosine as a foot-and-mouth disease vaccine adjuvant elicits robust host defense against viral infection through immunomodulation.

Kim H, Ko M, Shin S, Park S, Park J, Kim S Front Cell Infect Microbiol. 2024; 14:1331779.

PMID: 38510965 PMC: 10951065. DOI: 10.3389/fcimb.2024.1331779.


D-galacto-D-mannan-mediated Dectin-2 activation orchestrates potent cellular and humoral immunity as a viral vaccine adjuvant.

Kim H, Ko M, Park S, Shin S, Kim G, Kwak D Front Immunol. 2024; 15:1330677.

PMID: 38433834 PMC: 10904532. DOI: 10.3389/fimmu.2024.1330677.